Viewpoint Molecular Targeting Report issue

For profit Phase 1 Phase 2
Founded: Iowa City IA United States (2008)
Status: Acquired by IsoRay Medical, Inc. (2022)

Organization Overview

First Clinical Trial
2021
NCT04904120
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Viewpoint Molecular Targeting

Active Ingredients

Drugs in Phase 2 Trials (3)

Key: Viewpoint Molecular Targeting (0) Acquired (3)

[203pb]vmt01 (2 trials)

[212pb]vmt-α-net, (1 trial)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (2)

Key: Viewpoint Molecular Targeting (0) Acquired (2)

[203pb]vmt-α-net (1 trial)

[68ga]vmt02 (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 5
  • # of Trial APIs: 5